Press release from Companies
Published: 2015-04-09 15:37:33
WntResearch AB today announces that the European Patent Office (EPO) has informed on their homepage that a Decision to grant a European patent for EP 2 384 763, covering WntResearch’s important peptide Foxy-5, has been taken.
CEO Nils Brünner comments: “I am extremely satisfied that we are now having a European patent protection for our lead compound Foxy-5. It is especially gratifying to have this patent in place since it is our principal patent.” For additional information please contact: Nils Brünner, VD E-mail: firstname.lastname@example.org Telephone: + 45 2614 4708 About WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I - Foxy-5 - as well as one candidate drug in preclinical development - Box-5. The Company is currently focusing mainly on the development of Foxy-5.